...
首页> 外文期刊>Sensors >Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity
【24h】

Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity

机译:利用表面等离子体共振(SPR)技术鉴定具有抗血管生成活性的成纤维细胞生长因子2(FGF2)拮抗剂

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Angiogenesis, the process of new blood vessel formation, is implicated in various physiological/pathological conditions, including embryonic development, inflammation and tumor growth. Fibroblast growth factor-2 (FGF2) is a heparin-binding angiogenic growth factor involved in various physiopathological processes, including tumor neovascularization. Accordingly, FGF2 is considered a target for antiangiogenic therapies. Thus, numerous natural/synthetic compounds have been tested for their capacity to bind and sequester FGF2 in the extracellular environment preventing its interaction with cellular receptors. We have exploited surface plasmon resonance (SPR) technique in search for antiangiogenic FGF2 binders/antagonists. In this review we will summarize our experience in SPR-based angiogenesis research, with the aim to validate SPR as a first line screening for the identification of antiangiogenic compounds.
机译:血管生成是新血管形成的过程,涉及多种生理/病理状况,包括胚胎发育,炎症和肿瘤生长。成纤维细胞生长因子2(FGF2)是肝素结合血管生成生长因子,参与各种生理病理过程,包括肿瘤新血管形成。因此,FGF2被认为是抗血管生成疗法的靶标。因此,已经测试了多种天然/合成化合物在细胞外环境中结合和螯合FGF2的能力,从而阻止了其与细胞受体的相互作用。我们已经利用表面等离振子共振(SPR)技术来寻找抗血管生成的FGF2结合剂/拮抗剂。在这篇综述中,我们将总结我们在基于SPR的血管生成研究中的经验,以验证SPR作为鉴定抗血管生成化合物的一线筛选。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号